This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Comparison of the Effect of Vaseline and Bepanthen® "Wund- Und Heilsalbe" on the Wound Healing Following Laser Therapy

Sponsored by RWTH Aachen University

About this trial

Last updated 7 years ago

Study ID

16-011

Status

Completed

Type

Interventional

Phase

Phase 3

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 7 years ago

What is this trial about?

In the field of dermatology the healing process and therefore the success of a laser treatment are strongly determined by an appropriate postoperative treatment of the laser-treated skin. The manufacturer of CO2 laser systems recommends the application of Vaseline postoperatively to protect the treated tissue from air exposition until encrustation of the laser-treated skin decreases (usually after 7-14 days). An alternative to Vaseline could be Bepanthen® "Wund- und Heilsalbe" (Bayer). It contains the active ingredient pro-vitamin Dexapanthenol, which is widely used in dermatology therapy. The product helps to stabilize the protective barrier of the skin, to reduce the skin irritation, to stimulate the skin regeneration and to promote the wound healing. In an in-vitro study Bepanthen® "Wund- und Heilsalbe" triggered wound closure significantly faster compared to Vaseline. In this study the effect of Bepanthen® "Wund- und Heilsalbe" on wound healing should be investigated and compared to Vaseline in vivo following fractional ablative CO2 laser treatment of photo-damaged skin.

What are the participation requirements?

Yes

Inclusion Criteria

- Age ≥ 18 years

- photodamaged skin, which need to be treated with the fractional ablative CO2 laser

No

Exclusion Criteria

- pregnant or lactating females

- chronic diseases such as diabetes and vascular disease with impaired wound healing

- Patients, who tend to form hypertrophic scars and keloids

- Patients, who take the isotretinoin-containing medication in the past year

- topical or systemic corticosteroid treatment

- immunocompromised patients

- Patients with the Koebner phenomenon

- People with the skin type 6

- Patients with melanoma

Locations

Location

Status